IL103984A - Pharmaceutical compositions containing linked cyclic polyamines certain such novel compounds and their preparation - Google Patents

Pharmaceutical compositions containing linked cyclic polyamines certain such novel compounds and their preparation

Info

Publication number
IL103984A
IL103984A IL10398492A IL10398492A IL103984A IL 103984 A IL103984 A IL 103984A IL 10398492 A IL10398492 A IL 10398492A IL 10398492 A IL10398492 A IL 10398492A IL 103984 A IL103984 A IL 103984A
Authority
IL
Israel
Prior art keywords
bis
methylene
compound
acid addition
addition salt
Prior art date
Application number
IL10398492A
Other languages
English (en)
Other versions
IL103984A0 (en
Inventor
Gary James Bridger
Sreenivasan Padmanabhan
Renato Tony Skerlj
David Michael Thornton
Original Assignee
Johnson Matthey Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10706343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL103984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc
Publication of IL103984A0 publication Critical patent/IL103984A0/xx
Publication of IL103984A publication Critical patent/IL103984A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL10398492A 1991-12-16 1992-12-04 Pharmaceutical compositions containing linked cyclic polyamines certain such novel compounds and their preparation IL103984A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919126677A GB9126677D0 (en) 1991-12-16 1991-12-16 Improvements in chemical compounds

Publications (2)

Publication Number Publication Date
IL103984A0 IL103984A0 (en) 1993-05-13
IL103984A true IL103984A (en) 1998-10-30

Family

ID=10706343

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10398492A IL103984A (en) 1991-12-16 1992-12-04 Pharmaceutical compositions containing linked cyclic polyamines certain such novel compounds and their preparation

Country Status (26)

Country Link
US (2) USRE42152E1 (pl)
EP (2) EP0619813B1 (pl)
JP (1) JP3375961B2 (pl)
KR (1) KR100286235B1 (pl)
AT (1) ATE273964T1 (pl)
AU (1) AU661086B2 (pl)
CA (1) CA2125978C (pl)
CZ (1) CZ286928B6 (pl)
DE (2) DE122010000001I1 (pl)
DK (1) DK0619813T3 (pl)
ES (1) ES2224096T3 (pl)
FI (1) FI942849A0 (pl)
GB (1) GB9126677D0 (pl)
HK (1) HK1049328A1 (pl)
HU (1) HU224013B1 (pl)
IL (1) IL103984A (pl)
MX (1) MX9207316A (pl)
MY (1) MY110897A (pl)
NL (1) NL300425I1 (pl)
NO (2) NO305984B1 (pl)
NZ (1) NZ246179A (pl)
PL (1) PL173643B1 (pl)
PT (1) PT619813E (pl)
RU (1) RU94031208A (pl)
WO (1) WO1993012096A1 (pl)
ZA (1) ZA929632B (pl)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5663161A (en) * 1995-02-17 1997-09-02 The Research Foundation Of State University Of New York Anti-viral triaza compounds
US5612478A (en) * 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) * 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5608061A (en) * 1995-08-02 1997-03-04 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
RU2144532C1 (ru) * 1997-06-16 2000-01-20 Научно-исследовательский институт полимерных материалов Способ получения транс-1,4,5,8-тетранитрозо-1,4,5,8-тетраазадекалина
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP2002529502A (ja) * 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AP1654A (en) * 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
WO2000066112A1 (en) * 1999-05-03 2000-11-09 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
AU2334301A (en) * 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
EP1269258B1 (en) * 2000-02-22 2012-01-11 Brewer Science, Inc. Organic polymeric antireflective coatings deposited by chemical vapor deposition
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
US6734191B2 (en) * 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
HK1052011A1 (zh) 2000-09-15 2003-08-29 Anormed Inc. 趋化因子受体结合杂环化合物
DE60136476D1 (de) 2000-09-29 2008-12-18 Anormed Inc -stickstoffhaltigen zyklischen polyaminen und deren verbindungen
DE10117206A1 (de) * 2001-04-06 2002-10-10 Bayer Ag Verfahren zur Herstellung von halogensubstituierten Dibenzylalkoholen, diese halogensubstituierten Dibenzylalkohole sowie deren Verwendung
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DK1411918T3 (da) * 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
JP4431389B2 (ja) * 2001-09-12 2010-03-10 アノーメッド インコーポレイティド 鏡像異性的に純粋なアミノ置換縮合二環式環の合成
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
PL369856A1 (pl) 2001-12-21 2005-05-02 Anormed Inc. Związki heterocykliczne o zwiększonej skuteczności wiązania się do receptorów chemokinowych
JP4120586B2 (ja) * 2002-01-18 2008-07-16 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
JP4778420B2 (ja) 2003-04-22 2011-09-21 アノーメッド インコーポレイティド 増強された有効性を有するケモカインレセプタ結合複素環式化合物
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
EP1730113B1 (en) * 2004-03-15 2016-12-28 Genzyme Corporation Process for the synthesis of a cxcr4 antagonist
EP1783108B1 (en) * 2004-08-05 2010-12-22 Sumitomo Chemical Company, Limited Method for producing halogen-substituted benzenedimethanol
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
CA2586765A1 (en) * 2004-11-05 2006-12-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
WO2006138350A2 (en) * 2005-06-15 2006-12-28 Anormed Inc. Chemokine receptor binding compounds
CA2619881A1 (en) * 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
WO2007054783A2 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
KR101287752B1 (ko) 2006-01-24 2013-07-19 스미또모 가가꾸 가부시키가이샤 할로겐 치환 벤젠디메탄올의 제조 방법
CA2643209A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
US20100003224A1 (en) * 2006-08-02 2010-01-07 Genzyme Corporation Combination Therapy
CN101500595A (zh) * 2006-08-07 2009-08-05 健赞股份有限公司 组合治疗
US20080039475A1 (en) * 2006-08-08 2008-02-14 Akarx, Inc. Compositions and methods for increasing blood platelet levels in humans
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
EP2164953A4 (en) 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA
WO2009114614A2 (en) 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
EP2149567A1 (en) * 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
US8771677B2 (en) * 2008-12-29 2014-07-08 Vladimir B Serikov Colony-forming unit cell of human chorion and method to obtain and use thereof
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
WO2014125499A1 (en) 2013-02-13 2014-08-21 Natco Pharma Limited Improved and commercially viable process for the preparation of high pure plerixafor base
PT107018A (pt) * 2013-06-20 2014-12-22 Inst Superior Tecnico Síntese e uso de ciclamas com atividade antibacteriana
EP3038617A1 (en) 2013-08-30 2016-07-06 Ramot at Tel-Aviv University Ltd. Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling
ES2966886T3 (es) 2014-05-09 2024-04-24 Univ Yale Partículas recubiertas con poliglicerol hiperramificado y métodos de elaboración y uso de las mismas
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
WO2016081621A1 (en) 2014-11-18 2016-05-26 Yale University Formulations for targeted release of agents under low ph conditions and methods of use thereof
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2016176155A1 (en) 2015-04-25 2016-11-03 Poznansky Mark C Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
EP3302710A4 (en) 2015-06-03 2019-02-20 The University of Queensland MOBILIZERS AND USE THEREOF
KR20180043360A (ko) 2015-09-02 2018-04-27 프레세니어스 카비 온콜로지 리미티드 자일렌 결합된 사이클램 화합물의 제조방법
US11890348B2 (en) 2015-09-18 2024-02-06 The General Hospital Corporation Localized delivery of anti-fugetactic agent for treatment of cancer
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US20200308590A1 (en) 2016-02-16 2020-10-01 Yale University Compositions and methods for treatment of cystic fibrosis
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
US11453706B2 (en) 2016-09-09 2022-09-27 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018049120A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
WO2018049118A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
US11419894B2 (en) 2016-09-16 2022-08-23 The General Hospital Corporation Modified natural killer cells for the treatment of cancer
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
EP3600395A4 (en) 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
EP3703715A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US20190314407A1 (en) 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111712262A (zh) 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US20200338132A1 (en) 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US20220031633A1 (en) 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
JP2024545093A (ja) 2021-12-08 2024-12-05 イェール ユニバーシティー 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション
WO2023159189A1 (en) 2022-02-18 2023-08-24 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions
WO2025024693A1 (en) 2023-07-25 2025-01-30 Massachusetts Institute Of Technology Compositions and methods for treating fan1 associated trinucleotide repeat expansion disorders
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) * 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5047572A (en) * 1988-11-18 1991-09-10 Ici Americas Inc. Trisubstituted benzoic acid intermediates
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
CA2069886A1 (en) 1989-10-23 1991-04-24 David Love Multi-site metal chelating agents
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) * 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds

Also Published As

Publication number Publication date
ZA929632B (en) 1993-06-18
MY110897A (en) 1999-06-30
NL300425I1 (nl) 2010-01-04
NO2010001I2 (no) 2012-08-27
US5583131A (en) 1996-12-10
NO2010001I1 (no) 2010-03-08
HUT67544A (en) 1995-04-28
CZ118894A3 (en) 1995-10-18
PL173643B1 (pl) 1998-04-30
DK0619813T3 (da) 2004-12-20
WO1993012096A1 (en) 1993-06-24
HK1049328A1 (en) 2003-05-09
NO305984B1 (no) 1999-08-30
NO942254D0 (no) 1994-06-15
KR100286235B1 (ko) 2001-04-16
HU9401786D0 (en) 1994-09-28
EP0619813A1 (en) 1994-10-19
EP0619813B1 (en) 2004-08-18
FI942849A7 (fi) 1994-06-15
IL103984A0 (en) 1993-05-13
AU3165593A (en) 1993-07-19
JPH07501816A (ja) 1995-02-23
MX9207316A (es) 1993-06-01
CZ286928B6 (cs) 2000-08-16
RU94031208A (ru) 1996-09-10
HU224013B1 (hu) 2005-04-28
DE69233401T2 (de) 2005-10-13
JP3375961B2 (ja) 2003-02-10
CA2125978A1 (en) 1993-06-24
USRE42152E1 (en) 2011-02-15
ATE273964T1 (de) 2004-09-15
GB9126677D0 (en) 1992-02-12
AU661086B2 (en) 1995-07-13
DE122010000001I1 (de) 2010-08-26
PT619813E (pt) 2004-12-31
FI942849L (fi) 1994-06-15
HK1014368A1 (en) 1999-09-24
NO942254L (no) 1994-06-15
FI942849A0 (fi) 1994-06-15
ES2224096T3 (es) 2005-03-01
CA2125978C (en) 2005-09-20
DE69233401D1 (de) 2004-09-23
EP1223166A1 (en) 2002-07-17
NZ246179A (en) 1996-03-26

Similar Documents

Publication Publication Date Title
IL103984A (en) Pharmaceutical compositions containing linked cyclic polyamines certain such novel compounds and their preparation
CA2178272C (en) Antiviral monocyclic polyamines
EP0739345B1 (en) Cyclic polyamines
CN117800989A (zh) 一类含环外双键、多取代甲基醚结构的化合物及其应用
KR910006637B1 (ko) 트립타민 유도체의 제조방법
CZ286180B6 (cs) 6,9-bis(Substituované amino)benzo/g/isochinolin-5 10-diony
CN110452176A (zh) 吲唑类衍生物及其制备方法和用途
WO1992016494A1 (en) Long chain antiviral compounds
CN117865993B (zh) 一种aak1抑制剂及其制备和应用
JP2781073B2 (ja) 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
HK1014368B (en) Linked cyclic polyamines with activity against hiv
HK40096015A (zh) 适用於抗体-药物偶联物的毒素分子
TW202539636A (zh) 包含三併環的化合物、含有其的藥物組合物及用途
HK40096015B (zh) 适用於抗体-药物偶联物的毒素分子
CN121914139A (zh) 作为glp-1r激动剂的化合物
CN116751240A (zh) 2’-去氧-2’,2’-二氟胞苷碳酸酯酰肼的制备及其应用
HK1013995B (en) Derivatives of monocyclic polyamines, their preparation, and their use as antiviral agents
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法
JPH0834786A (ja) トリフルオロメチルピロロインドール誘導体及びその製造方法

Legal Events

Date Code Title Description
FF Patent granted
HP Change in proprietorship
KB Patent renewed
KB Patent renewed
KB Patent renewed
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted

Extension date: 20171204

EXTN Extension order renewed